KSV01 not checked

TCRx Therapeutics Co.Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“KSV01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries CD19 CAR.”In the company’s words, NCT07260812 on ClinicalTrials.gov
Tested for
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Main trialPhase 1
“This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.”In the company’s words, NCT07260812 on ClinicalTrials.gov

Other drugs for Non-Hodgkin Lymphoma

All 275 drugs for Non-Hodgkin Lymphoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 31 Dec 2028 KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow KSV01

Following is part of Solo: you see every change to KSV01 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in